SCHEMBL1010862

SCHEMBL1010862

CCNOc1ccc(Cl)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.38
PPARG P37231 2/20 0.38
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
SLC6A4 P31645 4/20 0.38
HTR2A P28223 4/20 0.37
KCNH2 Q12809 3/20 0.37
ABCB11 O95342 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
PMP22 Q01453 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11384402 0.79 CA1 (0.52) CYP3A4ALDH1A1RAB9AL3MBTL1GAA
SCHEMBL11577748 0.79 ACHE (0.44) DRD2DRD4DRD3CYP3A4TSHR
SCHEMBL11578631 0.77 MAPT (0.39) DRD2DRD4DRD3SLC6A4MAOA
Hydrochloric Acid SCHEMBL10512586 0.77 ACHE (0.42) DRD2DRD4DRD3CYP3A4TSHR
SCHEMBL4005266 0.77 CYP1A2 (0.40) DRD2DRD4DRD3SLC6A4CYP1A2
SCHEMBL507062 0.76 CA4 (0.42) SLC6A4TSHRMAOAL3MBTL1
SCHEMBL8059971 0.75 KMT2A (0.49) DRD2DRD4SLC6A4HTR2AKCNH2
Hydrochloric Acid SCHEMBL28211868 0.74 LTA4H (0.40) SLC6A4TSHRMAOAL3MBTL1
SCHEMBL11296171 0.74 HTR2A (0.42) PPARADRD2DRD4DRD3SLC6A4
SCHEMBL9487129 0.74 LTA4H (0.55) TSHRMAOAALDH1A1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026258-B2 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2011-09-27 US disclosed
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-20100120845-A1 ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2010-05-13 US disclosed
US-7674805-B2 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2010-03-09 US disclosed
US-20080312262-A1 ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2008-12-18 US disclosed
US-7439257-B2 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2008-10-21 US disclosed
EP-1708994-B1 ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2007-08-08 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-20070021424-A1 ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed
US-4119729-A TREATMENT OF HYPERTENSION MEAD JOHNSON & COMPANY (US) 1978-10-10 US disclosed
US-4067904-A ANTIARRHYTHMIA, HYPOTENSIVE MEAD JOHNSON & COMPANY (US) 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885DRD2 863/4885
US-20070021424-A1 ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS CMBL, ALK, ALKBH1 PPARA 3030/4885PPARG 3662/4885DRD2 3805/4885
US-20100120845-A1 ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS CMBL, ALK, ALKBH1 PPARA 3030/4885PPARG 3662/4885DRD2 3805/4885
US-20080312262-A1 ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS CMBL, ALK, ALKBH1 PPARA 3030/4885PPARG 3662/4885DRD2 3805/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885DRD2 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.